Profil bibliographique

Wassim McHayleh

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

7Publications signalées

2Citations signalées

2Affiliations récentes

Les institutions déclarées

AdventHealth Orlando Florida Hospital Cancer Institute

Les domaines associés

Advanced Breast Cancer TherapiesHER2/EGFR in Cancer ResearchCancer Immunotherapy and BiomarkersBreast Cancer Treatment StudiesCancer Treatment and Pharmacology

Les publications récentes

Accès ouvert 2026 article OpenAlex

Elacestrant in Combination with Everolimus for Estrogen Receptor-Positive, HER2-Negative Previously Treated Advanced Breast Cancer: Results from ELEVATE

Hope S. Rugo, Sara M. Tolaney, Nancy Chan, G. Borges et autres

us, br, il, it, es, be, de (code pays fourni par la source)

0 citations Clinical Cancer Research

Accès ouvert 2026 article OpenAlex

Response to Zona, E.E.; Israel, J.S. Toward Individualized Management: A Commentary on Perioperative Systemic Therapy Guidelines in Breast Cancer Surgery and Reconstruction. Comment on “Galuia et al. Perioperative Drug Management of Systemic Therapies in Breast Cancer: A Literature Review and Treatment Recommendations. Curr. Oncol. 2025, 32, 154”

Mariem Galuia, Julia Fedorova, E. Mamounas, Sabrina Pavri et autres

us (code pays fourni par la source)

0 citations Current Oncology

2026 article OpenAlex

Progression-free survival after next line of treatment (PFS2) and subsequent therapies (subs tx) in the ASCENT-04 study of participants (pts) with previously untreated PD-L1+ metastatic triple-negative breast cancer (mTNBC) treated with sacituzumab govitecan (SG) plus pembrolizumab (pembro) vs chemotherapy (chemo) plus pembro.

Kevin Kalinsky, P Schmid, Evandro de Azambuja, S Loi et autres

us, gb, be, au, kr, Afrique du Sud, fr, ca, jp, mx, br (code pays fourni par la source)

2 citations Journal of Clinical Oncology

Accès ouvert 2026 conference-abstract OpenAlex

Adjuvant and neoadjuvant evaluation of a structural variant-based MRD assay in early breast cancer: A real-world cohort.

Jason Carey, Jennifer Yen, Daniel Sumarriva, Taryn Cranford et autres

us (code pays fourni par la source)

0 citations Journal of Clinical Oncology

Accès ouvert 2026 conference-abstract OpenAlex

ASCENT-04: Analysis of efficacy by biomarker subgroups with sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in participants (pts) with previously untreated PD-L1+ metastatic triple-negative breast cancer (mTNBC).

Sara M. Tolaney, P Schmid, Evandro de Azambuja, Kevin Kalinsky et autres

us, gb, be, kr, Afrique du Sud, fr, ca, jp, mx, br, au (code pays fourni par la source)

0 citations Journal of Clinical Oncology

2026 conference-abstract OpenAlex

Elacestrant in combination with capivasertib in patients with ER+/HER2− advanced breast cancer: Update from ELEVATE, a phase 1b/2, open-label, umbrella study.

Wassim McHayleh, S M Tolaney, Virginia Kaklamani, Mridula George et autres

us, gb, it (code pays fourni par la source)

0 citations Journal of Clinical Oncology

2026 conference-abstract OpenAlex

Abstract CT262: Elacestrant (Ela) in combination with everolimus (Eve) or abemaciclib (Abema) in patients with ER+/HER2- locally advanced or metastatic breast cancer mBC: phase 2 results from ELEVATE, an open-label, umbrella study

Hope S. Rugo, Sara M. Tolaney, Nancy Chan, Giuliano Borges et autres

us, br, il, it, ch (code pays fourni par la source)

0 citations Cancer Research

Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.